Table 1 Baseline characteristics of the study population according to the occurrence of MACE
Variables | Total (n = 1100) | Without event (n = 857) | With event (n = 243) | p-value |
|---|---|---|---|---|
General conditions | ||||
Age (years) | 62.84 ± 8.28 | 62.41 ± 8.29 |  64.33± 8.10 | 0.001 |
Male, n (%) | 760 (69.1) | 596 (69.5) | 164 (67.5) | 0.582 |
BMI (kg/m2) | 25.66 ± 3.63 | 25.55 ± 3.55 | 26.02 ± 3.88 | 0.075 |
LVEF (%) | 60.00 (54.00–65.00) | 60.00 (55.00–65.00) | 60.00 (50.00–65.00) | 0.002 |
FH-CAD, n (%) | 215 (19.6) | 166 (19.4) | 49 (20.2) | 0.783 |
Admission for MI, n (%) | 197 (17.9) | 155 (18.1) | 42 (17.3) | 0.778 |
Medical history, n (%) | ||||
Previous MI | 215 (19.5) | 160 (18.7) | 55 (22.6) | 0.170 |
Pervious stroke | 165 (15.0) | 121 (14.1) | 44 (18.1) | 0.128 |
Previous PCI | 114 (10.4) | 91 (10.6) | 23 (9.5) | 0.636 |
Hypertension | 693 (63.0) | 529 (61.7) | 164 (67.5) | 0.114 |
DM | 363 (33.0) | 273 (31.9) | 90 (37.0) | 0.142 |
Hyperlipidemia | 372 (33.8) | 283 (33.0) | 89 (36.6) | 0.318 |
Laboratory text | ||||
FBG (mmol/L) | 5.36 (4.75–6.85) | 5.25 (4.70–6.59) | 5.73 (4.85–8.30) |  < 0.001 |
TC (mmol/L) | 4.27 ± 1.13 | 4.18 ± 1.24 | 4.58 ± 1.04 |  < 0.001 |
LDL-C (mmol/L) | 2.45 (1.93–3.04) | 2.42 (1.90–2.96) | 2.59 (2.01–3.31) | 0.008 |
HDL-C (mmol/L) | 1.13 ± 0.26 | 1.14 ± 0.25 | 1.09 ± 0.28 | 0.012 |
TG (mmol/L) | 1.32 (0.98–1.76) | 1.25 (0.97–1.69) | 1.49 (1.13–2.05) |  < 0.001 |
eGFR (ml/min/1.73m2) | 106.74 ± 30.04 | 107.84 ± 30.54 | 102.85 ± 27.91 | 0.022 |
UA (µmol/L) | 303.00 (256.00–361.00) | 299.00 (254.00–356.00) | 314.00 (266.75–378.25) | 0.009 |
Cardiovascular medications, n (%) | ||||
Antiplatelet drugs | 1089 (99.0) | 849 (99.1) | 240 (98.8) | 0.715 |
Statins | 898 (81.6) | 695 (81.1) | 203 (83.5) | 0.400 |
Beta-blockers | 973 (88.5) | 775 (90.4) | 198 (81.5) |  < 0.001 |
ACEI/ARB | 172 (15.6) | 129 (15.1) | 43 (17.7) | 0.318 |
Hypoglycemic drugs | 262 (23.8) | 203 (23.7) | 59 (24.3) | 0.865 |
METS-IR | 40.01 ± 6.90 | 39.52 ± 6.63 | 41.73 ± 7.53 |  < 0.001 |